Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00517322
Recruitment Status : Unknown
Verified August 2007 by Università degli Studi dell'Insubria.
Recruitment status was:  Recruiting
First Posted : August 16, 2007
Last Update Posted : August 16, 2007
Information provided by:
Università degli Studi dell'Insubria

August 15, 2007
August 16, 2007
August 16, 2007
August 2007
Not Provided
  • left atrial volume [ Time Frame: one year ]
  • diastolic function [ Time Frame: one year ]
Same as current
No Changes Posted
systolic and diastolic blood pressure [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
Aim of the study is to compare in hypertensive patients the effect of one year therapy with ACE-inhibitor (RAMIPRIL) or angiotensin II receptor blocker (IRBESARTAN) on left atrial remodelling and diastolic function.
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Left Atrial Volume
  • Hypertensive Heart Disease
  • Antihypertensive Drugs
  • Diastolic Function
  • Renin Angiotensin System
  • Drug: ramipril
    ramipril 2.5- 5 mg once daily
  • Drug: irbesartan
    irbesartan 150-300 mg once daily
  • Experimental: 1
    treatment with ramipril
    Intervention: Drug: ramipril
  • Experimental: 2
    treatment with irbesartan
    Intervention: Drug: irbesartan

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
August 2010
Not Provided

Inclusion Criteria:·

  • mild to moderate essential hypertension
  • no antihypertensive treatment
  • good quality echocardiogram

Exclusion Criteria:

  • cardiovascular diseases (AMI, stroke o TIA)
  • heart failure, valvular heart disease
  • diabetes
  • secondary hypertension
  • atrial fibrillation
  • hepatic and renal severe failure
  • pregnancy
Sexes Eligible for Study: All
40 Years to 65 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Università degli Studi dell'Insubria
Not Provided
Principal Investigator: anna maria grandi, MD Università degli Studi dell'Insubria
Università degli Studi dell'Insubria
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP